

2146 E. Hamlin St.
Seattle WA 98112

May 15, 1999

1244 '99 MAY 21 A10:18

Dockets Management Branch
FDA
5630 Fishers Lane, Room 1061
Rockville MD 20857-0003

Dear Sirs :

I am writing to express concern about Docket 98N-1265 regarding Section 503A of the FDA Modernization Act of 1997.

I believe the MOU as drafted unnecessarily restricts both consumer choice as well as commonly accepted professional pharmacy compounding practices. I believe that:

- Restrictions on interstate compounding commerce should not be enacted beyond current standards;
- Pharmacists should be able to suggest alternative compounded as an alternative to patented drugs;
- Specialty pharmacies serve a distinct and valuable role. They are not located in all states, nor is there a valid reason to restrict their transactions to a single state : to do so will create hardships for a significant portion of the U.S population.

Please ask that you amend the MOU referenced above no later than May 27, 1999, to correct its current overreaching as noted above.

Q8N-1265

Sincerely yours, C2513
Doug Forbes

Attn: Docket# 98N-1265

Dockets Management Branch (HFA-305)
Food & Drug Administration
5630 Fishers Lane, Room 1061
Rockville MD

20857 -0003

20857-0003 

